NCT06284564 2026-03-04A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)M.D. Anderson Cancer CenterPhase 2 Active not recruiting10 enrolled